Slide 022 Interventions for Tuberculosis Control and Elimination
next Next
previous Previous
beginning First
last Last

Rifampicin has a crystalline structure and its manufacturing may negatively influence the pharmacokinetic properties of the drug.

Similarly, just changing the excipient and the manufacturing process changes the pharmacokinetics of rifampicin.

It is therefore critical to require bioavailability studies from potential suppliers.  Such studies should preferably be performed by an independent university.

Go to top

Last update: September 29, 2010